HE 184/2016 vp StV 27.10.2016 Suomen Sydänliitto ry Asiantuntijalausunto

This procedure concerns an expert statement from the Finnish Heart Association regarding health insurance, drug reimbursements, wholesale prices, price competition, and parallel imports of medicines. It addresses potential impacts on the pharmaceutical market and patient access to treatments. The statement is relevant to patients, pharmaceutical companies, and healthcare providers in Finland. It may influence future policy decisions on drug pricing and reimbursement schemes within the Finnish healthcare system.